Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1976 1
1977 1
1979 1
1981 2
1983 4
1985 1
1986 2
1988 4
1989 4
1990 3
1991 1
1992 5
1993 5
1994 6
1995 2
1996 6
1997 8
1998 4
1999 11
2000 5
2001 10
2002 16
2003 7
2004 11
2005 10
2006 16
2007 11
2008 10
2009 16
2010 10
2011 15
2012 21
2013 20
2014 24
2015 22
2016 23
2017 26
2018 27
2019 31
2020 37
2021 39
2022 38
Text availability
Article attribute
Article type
Publication date

Search Results

475 results
Results by year
Filters applied: . Clear all The following terms were ignored: %, %, %, % The following terms were not found in PubMed: 22Sidossis, 5BAuthor
Page 1
Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial.
Reck M, Schenker M, Lee KH, Provencio M, Nishio M, Lesniewski-Kmak K, Sangha R, Ahmed S, Raimbourg J, Feeney K, Corre R, Franke FA, Richardet E, Penrod JR, Yuan Y, Nathan FE, Bhagavatheeswaran P, DeRosa M, Taylor F, Lawrance R, Brahmer J. Reck M, et al. Eur J Cancer. 2019 Jul;116:137-147. doi: 10.1016/j.ejca.2019.05.008. Epub 2019 Jun 11. Eur J Cancer. 2019. PMID: 31195357 Free article. Clinical Trial.
During treatment, mean changes from baseline with nivolumab + ipilimumab showed early, clinically meaningful improvements in LCSS ASBI/3-IGI and EQ-5D VAS/UI; with chemotherapy, symptoms and health-related quality of life remained stable (LCSS ASBI/3-IGI, EQ-5D UI) …
During treatment, mean changes from baseline with nivolumab + ipilimumab showed early, clinically meaningful improvements in LCSS ASBI/3-IGI …
Timing and Dose of Upper Limb Motor Intervention After Stroke: A Systematic Review.
Hayward KS, Kramer SF, Dalton EJ, Hughes GR, Brodtmann A, Churilov L, Cloud G, Corbett D, Jolliffe L, Kaffenberger T, Rethnam V, Thijs V, Ward N, Lannin N, Bernhardt J. Hayward KS, et al. Stroke. 2021 Nov;52(11):3706-3717. doi: 10.1161/STROKEAHA.121.034348. Epub 2021 Oct 4. Stroke. 2021. PMID: 34601901
Timing of intervention start has not changed (median 38 days, interquartile range [IQR], 22-66) and study sample size remains small (median n=30, IQR 20-48). ...
Timing of intervention start has not changed (median 38 days, interquartile range [IQR], 22-66) and study sample size remains small ( …
Post-intensive care syndrome after a critical COVID-19: cohort study from a Belgian follow-up clinic.
Rousseau AF, Minguet P, Colson C, Kellens I, Chaabane S, Delanaye P, Cavalier E, Chase JG, Lambermont B, Misset B. Rousseau AF, et al. Ann Intensive Care. 2021 Jul 29;11(1):118. doi: 10.1186/s13613-021-00910-9. Ann Intensive Care. 2021. PMID: 34324073 Free PMC article.
They benefited from a standardized assessment, addressing health-related quality of life (EQ-5D-3L), sleep disorders (PSQI), and the three principal components of post-intensive care syndrome (PICS): physical status (Barthel index, handgrip and quadriceps strength), mental …
They benefited from a standardized assessment, addressing health-related quality of life (EQ-5D-3L), sleep disorders (PSQI), and the …
Comparing the EQ-5D-3 L and EQ-5D-5 L: studying measurement and scores in Indonesian type 2 diabetes mellitus patients.
Arifin B, Purba FD, Herman H, Adam JMF, Atthobari J, Schuiling-Veninga CCM, Krabbe PFM, Postma MJ. Arifin B, et al. Health Qual Life Outcomes. 2020 Feb 7;18(1):22. doi: 10.1186/s12955-020-1282-y. Health Qual Life Outcomes. 2020. PMID: 32028954 Free PMC article.
Two versions of the EQ-5D are available: the 3-level version (EQ-5D-3 L) and the 5-level version (EQ-5D-5 L). This study aims to compare specific measurement properties and scoring of the EQ-5D-3 L (3 L) and EQ-5D-5 …
Two versions of the EQ-5D are available: the 3-level version (EQ-5D-3 L) and the 5-level version (EQ-5D-5 L
A head-to-head comparison of EQ-5D-5 L and SF-6D in Chinese patients with low back pain.
Ye Z, Sun L, Wang Q. Ye Z, et al. Health Qual Life Outcomes. 2019 Apr 11;17(1):57. doi: 10.1186/s12955-019-1137-6. Health Qual Life Outcomes. 2019. PMID: 30971265 Free PMC article.
EQ-5D-5 L demonstrated better performance for most groups except location and general health grouped by the general assessment of health item from SF-36. Furthermore, when we applied ODI as external indicator of health status, the area under the ROC curve for EQ- …
EQ-5D-5 L demonstrated better performance for most groups except location and general health grouped by the general assessment …
Health-Related Quality of Life Among Patients With HR+/HER2- Early Breast Cancer.
Criscitiello C, Spurden D, Piercy J, Rider A, Williams R, Mitra D, Wild R, Corsaro M, Kurosky SK, Law EH. Criscitiello C, et al. Clin Ther. 2021 Jul;43(7):1228-1244.e4. doi: 10.1016/j.clinthera.2021.04.020. Epub 2021 Jul 11. Clin Ther. 2021. PMID: 34256965
Of these, 1102 completed the FACT-B and 1083 completed the EQ-5D-5L questionnaires. The mean (SD) FACT-B total score was 99.0 (21.9). ...In addition, mean scores were comparable between the active adjuvant treatment and postadjuvant surveillance groups for the FACT-B total …
Of these, 1102 completed the FACT-B and 1083 completed the EQ-5D-5L questionnaires. The mean (SD) FACT-B total score was 99.0 (21.9). …
[Clinical characteristics and risk factors of recurrent Kawasaki disease].
Tan AX, Tang XM. Tan AX, et al. Zhonghua Er Ke Za Zhi. 2021 Dec 2;59(12):1038-1042. doi: 10.3760/cma.j.cn112140-20210827-00710. Zhonghua Er Ke Za Zhi. 2021. PMID: 34856662 Chinese.
Compared with the first episode, the second episode had lower white blood cell count (15.2 (12.8-18.8)10(9) vs. 18.0 (14.9-23.4)10(9)/L, Z=-2.462, P=0.014) and rate of edema in extremities (54% (22/41) vs. 76% (31/41), chi(2)=4.321, P=0.038), shorter fever durations …
Compared with the first episode, the second episode had lower white blood cell count (15.2 (12.8-18.8)10(9) vs. 18.0 (14.9-23.4)10(9)/L
The quality of life of the patients with diabetes type 2 using EQ-5D-5 L in Birjand.
Abedini MR, Bijari B, Miri Z, Shakhs Emampour F, Abbasi A. Abedini MR, et al. Health Qual Life Outcomes. 2020 Jan 30;18(1):18. doi: 10.1186/s12955-020-1277-8. Health Qual Life Outcomes. 2020. PMID: 32000785 Free PMC article.
Data were collected using a checklist including patients' demographic, clinical and laboratory information and the EQ-5D-5 L. Data were entered the SPSS (22) software, analyzed by independent sample T-test, ANOVA, Chi-Square and logistic regression tests. ... …
Data were collected using a checklist including patients' demographic, clinical and laboratory information and the EQ-5D-5 L. …
Biochemistry of iodothyronine deiodination.
Köhrle J. Köhrle J. Acta Med Austriaca. 1988;15 Suppl 1:22-4. Acta Med Austriaca. 1988. PMID: 3051830 Review.
Extrathyroidal deiodination of the thyroidal main secretory product L-T4, which may have prohormone functions, reveals hormonally active and potentially regulatory potent triiodothyronines. ...
Extrathyroidal deiodination of the thyroidal main secretory product L-T4, which may have prohormone functions, reveals hormonally act …
Influence of micropile parameters on bearing capacity of footings.
Malik BA, Shah MY, Sawant VA. Malik BA, et al. Environ Sci Pollut Res Int. 2021 Sep;28(35):48274-48283. doi: 10.1007/s11356-021-14062-7. Epub 2021 Apr 27. Environ Sci Pollut Res Int. 2021. PMID: 33904133
As the diameter of micropiles is progressively increased from 10 to 20 mm, the bearing capacity improves by around 27%. As the micropile spacing decreases from five times diameter (5d) to three times diameter (3d), the footing system's bearing capacity increases nearly by …
As the diameter of micropiles is progressively increased from 10 to 20 mm, the bearing capacity improves by around 27%. As the micropile spa …
475 results